Surgery pp 2123-2149 | Cite as

Nutritional Care of Cancer Patients

  • David A. August
  • Maureen B. Huhmann


The lay press and professional journals are replete with articles concerning the use of various nutrition interventions to treat, palliate, and support cancer patients.


Parenteral Nutrition Enteral Nutrition Total Parenteral Nutrition Nutrition Support Megestrol Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Warren S. The immediate cause of death in cancer. Am J Med Sci 1932;185:610–615.Google Scholar
  2. 2.
    Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer patients. Cancer (Phila) 1974;33(2):568–573.PubMedCrossRefGoogle Scholar
  3. 3.
    Studley H. Percentage of weight loss. JAMA 1936;106:458–460.Google Scholar
  4. 4.
    Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery (St. Louis) 1968;64(1):134–142.PubMedGoogle Scholar
  5. 5.
    Copeland EM III, Jonathan E. Rhoads lecture. Intravenous hyperalimentation and cancer. A historical perspective. JPEN J Parenter Enteral Nutr 1986;10(4):337–342.PubMedCrossRefGoogle Scholar
  6. 6.
    Copeland EM, Macfayden BV Jr, Dudrick SJ. Intravenous hyperalimentation in cancer patients. J Surg Res 1974;16(3):241–247.PubMedCrossRefGoogle Scholar
  7. 7.
    Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. JPEN J Parenter Enteral Nutr 1997;21(3):133–156.PubMedCrossRefGoogle Scholar
  8. 8.
    Kern KA, Norton JA. Cancer cachexia. JPEN J Parenter Enteral Nutr 1988;12(3):286–298.PubMedCrossRefGoogle Scholar
  9. 9.
    Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med 1981;305(7):375–382.PubMedCrossRefGoogle Scholar
  10. 10.
    Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991;51(12):3198–3203.PubMedGoogle Scholar
  11. 11.
    DeWys WD. Anorexia as a general effect of cancer. Cancer (Phila) 1979,43(5 suppl):2013–2019.PubMedCrossRefGoogle Scholar
  12. 12.
    Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491–497.PubMedCrossRefGoogle Scholar
  13. 13.
    Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 1995;22(2 suppl 3):98–111.PubMedGoogle Scholar
  14. 14.
    Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997;24(3):277–287.PubMedGoogle Scholar
  15. 15.
    MacDonald N. Is there evidence for earlier intervention in cancer-associated weight loss? J Support Oncol 2003;1(4):279–286.PubMedGoogle Scholar
  16. 16.
    Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003;4(11):686–694.PubMedCrossRefGoogle Scholar
  17. 17.
    Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003;1(3):159–168.PubMedGoogle Scholar
  18. 18.
    Lowry SF. Cancer cachexia revisited: old problems and new perspectives. Eur J Cancer 1991;27(1):1–3.PubMedGoogle Scholar
  19. 19.
    Costa G, Bewley P, Aragon M, Siebold J. Anorexia and weight loss in cancer patients. Cancer Treat Rep 1981;65(suppl 5):3–7.PubMedGoogle Scholar
  20. 20.
    Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997;13(1):1–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer (Phila) 1989;63(2):330–334.PubMedCrossRefGoogle Scholar
  22. 22.
    Chang A, August D. Acute abdomen, bowel obstruction, and fistula. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, eds. Clinical Oncology. New York: Churchill Livingstone, 1995:583–597.Google Scholar
  23. 23.
    Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12(1):213–225.PubMedGoogle Scholar
  24. 24.
    Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219(4):325–331.PubMedCrossRefGoogle Scholar
  25. 25.
    Hansell DT, Davies JW, Burns HJ. The relationship between resting energy expenditure and weight loss in benign and malignant disease. Ann Surg 1986;203(3):240–245.PubMedCrossRefGoogle Scholar
  26. 26.
    Arbeit JM, Lees DE, Corsey R, Brennan MF. Resting energy expenditure in controls and cancer patients with localized and diffuse disease. Ann Surg 1984;199(3):292–298.PubMedCrossRefGoogle Scholar
  27. 27.
    Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg 1983;197(2):152–162.PubMedCrossRefGoogle Scholar
  28. 28.
    Hyltander A, Drott C, Korner U, Sandstrom R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 1991;27(1):9–15.PubMedGoogle Scholar
  29. 29.
    Norton JA, Moley JF, Green MV, Carson RE, Morrison SD. Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res 1985;45(11 pt 1):5547–5552.PubMedGoogle Scholar
  30. 30.
    Stovroff MC, Fraker DL, Norton JA. Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg 1989;124(1):94–99.PubMedGoogle Scholar
  31. 31.
    Tisdale MJ. Tumor-host interactions. J Cell Biochem 2004;93(5):871–877.PubMedCrossRefGoogle Scholar
  32. 32.
    Lind D, Souba W, Copeland E. Weight loss and cachexia. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, eds. Clinical Oncology. New York: Churchill Livingstone, 1995:393–407.Google Scholar
  33. 33.
    Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985;161(5):984–995.PubMedCrossRefGoogle Scholar
  34. 34.
    Garcia-Martinez C, Costelli P, Lopez-Soriano FJ, Argiles JM. Is TNF really involved in cachexia? Cancer Invest 1997;15(1):47–54.PubMedCrossRefGoogle Scholar
  35. 35.
    Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167(3):1211–1227.PubMedCrossRefGoogle Scholar
  36. 36.
    Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50(4):555–563.PubMedCrossRefGoogle Scholar
  37. 37.
    Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 1990;86(6):2014–2024.PubMedCrossRefGoogle Scholar
  38. 38.
    Tracey Kf, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet 1989;1(8647):1122–1126.PubMedCrossRefGoogle Scholar
  39. 39.
    Toomey D, Redmond HP, Bouchier-Hayes D. Mechanisms mediating cancer cachexia. Cancer (Phila) 1995;76(12):2418–2426.PubMedCrossRefGoogle Scholar
  40. 40.
    Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004;7(4):427–434.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003;66(10):593–598.PubMedGoogle Scholar
  42. 42.
    Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78(10):554–561.PubMedCrossRefGoogle Scholar
  43. 43.
    Dulger H, Alici S, Sekeroglu MR, et al. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract 2004;58(6):545–549.PubMedCrossRefGoogle Scholar
  44. 44.
    Matthys P, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer 1991;49(1):77–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991;27(2):182–187.PubMedGoogle Scholar
  46. 46.
    Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia. Cancer Res 1991;51(9):2302–2306.PubMedGoogle Scholar
  47. 47.
    Fischer E, Marano MA, Barber AE, et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am J Physiol 1991;261(2 pt 2):R442–R452.PubMedGoogle Scholar
  48. 48.
    Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/ tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989;170(5):1627–1633.PubMedCrossRefGoogle Scholar
  49. 49.
    Gelin J, Moldawer LL, Lonnroth C, et al. Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma. Biochem Biophys Res Commun 1988;157(2):575–579.PubMedCrossRefGoogle Scholar
  50. 50.
    Espat NJ, Moldawer LL, Copeland EM III. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J Surg Oncol 1995;58(2):77–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res 2004,10(17):5862–5869.PubMedCrossRefGoogle Scholar
  52. 52.
    Martignoni ME, Kunze P, Friess H. Cancer cachexia. Mol Cancer 2003;2(1):36.PubMedCrossRefGoogle Scholar
  53. 53.
    Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2(11):862–871.PubMedCrossRefGoogle Scholar
  54. 54.
    Chamberlain JS. Cachexia in cancer-zeroing in on myosin. N Engl J Med 2004;351(20):2124–2125.PubMedCrossRefGoogle Scholar
  55. 55.
    Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004;114(3):370–378.PubMedGoogle Scholar
  56. 56.
    Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117(3):399–412.PubMedCrossRefGoogle Scholar
  57. 57.
    Bergstrom DA, Perm BH, Strand A, Perry RL, Rudnicki MA, Tapscott SJ. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol Cell 2002;9(3):587–600.PubMedCrossRefGoogle Scholar
  58. 58.
    Rofe AM, Bourgeois CS, Coyle P, Taylor A, Abdi EA. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res 1994;14(2B):647–650.PubMedGoogle Scholar
  59. 59.
    Moley J, Peacock J, Morrison S. Insulin reversal in cancer induced protein loss. Surg Forum 1985;36:416–419.Google Scholar
  60. 60.
    Moley JF, Morrison SD, Norton JA. Insulin reversal of cancer cachexia in rats. Cancer Res 1985;45(10):4925–4931.PubMedGoogle Scholar
  61. 61.
    Morrison SD. Feeding response of tumor-bearing rats to insulin and insulin withdrawal and the contribution of autonomous tumor drain to cachectic depletion. Cancer Res 1982;42(9):3642–3647.PubMedGoogle Scholar
  62. 62.
    Lundholm K, Holm G, Schersten T. Insulin resistance in patients with cancer. Cancer Res 1978;38(12):4665–4670.PubMedGoogle Scholar
  63. 63.
    Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA. Altered glucose metabolism in metastatic carcinoma. Cancer Res 1975;35(12):3710–3714.PubMedGoogle Scholar
  64. 64.
    Waterhouse C. Lactate metabolism in patients with cancer. Cancer (Phila) 1974;33(1):66–71.PubMedCrossRefGoogle Scholar
  65. 65.
    Waterhouse C, Jeanpretre N, Keilson J. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res 1979;39(6 pt 1):1968–1972.PubMedGoogle Scholar
  66. 66.
    Lundholm K, Edstrom S, Karlberg I, Ekman L, Schersten T. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer (Phila) 1982;50(6):1142–1150.PubMedCrossRefGoogle Scholar
  67. 67.
    Kralovic RC, Zepp FA, Cenedella RJ. Studies of the mechanism of carcass fat depletion in experimental cancer. Eur J Cancer 1977;13(10):1071–1079.PubMedGoogle Scholar
  68. 68.
    Mueller PS, Watkin DM. Plasma unesterfiled fatty acid concentrations in neoplastic disease. J Lab Clin Med 1961;57:95–108.PubMedGoogle Scholar
  69. 69.
    Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 1987;205(4):368–376.PubMedCrossRefGoogle Scholar
  70. 70.
    Dilman VM, Berstein LM, Ostroumova MN, Tsyrlina YV, Golubev AG. Peculiarities of hyperlipidaemia in tumour patients. Br J Cancer 1981;43(5):637–643.PubMedGoogle Scholar
  71. 71.
    Hussey HJ, Tisdale MJ. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 1994,70(1 ):6–10.PubMedGoogle Scholar
  72. 72.
    Jeevanandam M, Legaspi A, Lowry SF, Horowitz GD, Brennan MF. Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease. JPEN J Parenter Enteral Nutr 1988;12(3):229–236.PubMedCrossRefGoogle Scholar
  73. 73.
    Norton JA, Stein TP, Brennan MF. Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. Ann Surg 1981;194(2):123–128.PubMedCrossRefGoogle Scholar
  74. 74.
    Lundholm K, Bylund AC, Holm J, Schersten T. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 1976;12(6):465–473.PubMedGoogle Scholar
  75. 75.
    Lundholm K, Bennegard K, Eden E, Svaninger G, Emery PW, Rennie MJ. Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res 1982;42(11):4807–4811.PubMedGoogle Scholar
  76. 76.
    Warren RS, Jeevanandam M, Brennan MF. Comparison of hepatic protein synthesis in vivo versus in vitro in the tumor-bearing rat. J Surg Res 1987,42(1):43–50.PubMedCrossRefGoogle Scholar
  77. 77.
    Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, Shenkin A. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213(1):26–31.PubMedCrossRefGoogle Scholar
  78. 78.
    Moldawer L, Andersson C, Lonnroth C. Mechanisms of hypoalbuminemia in experimental cancer. J Parenter Enteral Nutr 1987;11:3S.Google Scholar
  79. 79.
    Moldawer LL, Rogy MA, Lowry SF. The role of cytokines in cancer cachexia. JPEN J Parenter Enteral Nutr 1992;16(6 suppl):43S–49S.PubMedGoogle Scholar
  80. 80.
    McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enteral Nutr 1992;16(6 suppl):50S–55S.PubMedGoogle Scholar
  81. 81.
    Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997;17(5):477–498.PubMedCrossRefGoogle Scholar
  82. 82.
    Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001;17(1 suppl):S1–S20.PubMedCrossRefGoogle Scholar
  83. 83.
    Yeh S, Wu SY, Levine DM, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000;4(4):246–251.PubMedGoogle Scholar
  84. 84.
    Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11(1):152–154.PubMedGoogle Scholar
  85. 85.
    Bolen JC, Andersen RE, Bennett RG. Deep vein thrombosis as a complication of megestrol acetate therapy among nursing home residents. J Am Med Dir Assoc 2000;1(6):248–252.PubMedGoogle Scholar
  86. 86.
    Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 15 2002;20(2):567–573.PubMedCrossRefGoogle Scholar
  87. 87.
    Anonymous. More on megestrol for prevention and treatment of cancer-associatied cachexia. Cancer Oncol Alerts 1998;13:21–22.Google Scholar
  88. 88.
    Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer (Phila) 1998;82(3):553–560.PubMedCrossRefGoogle Scholar
  89. 89.
    Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study. J Clin Endocrinol Metab 1995;80(7):2082–2087.PubMedCrossRefGoogle Scholar
  90. 90.
    Von Roenn JH, Tchekmedyian S, Hoffman RM, Chang C-Y, Ottery FD. Oxandrolone in cancer-related weight loss: improvement in weight, body cell mass (BCM), performance status, and quality of life (QOL). Paper presented at: 38th Annual ASCO Meeting; May 15–22, 2002, Orlando, FL.Google Scholar
  91. 91.
    Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10(1):14–18.PubMedGoogle Scholar
  92. 92.
    Wadleigh R, Spaulding M, Lembersky B, et al. Dronabinol enhancement of appetite in cancer patients (abstract). Proc Am Soc Clin Oncol 1990;9:1280.Google Scholar
  93. 93.
    Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64(6):1943–1950.PubMedCrossRefGoogle Scholar
  94. 94.
    Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A(8):1340–1343.PubMedCrossRefGoogle Scholar
  95. 95.
    Lissoni P, Barni S, Tancini G, et al. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J Biol Regul Homeost Agents 1994;8(4):126–129.PubMedGoogle Scholar
  96. 96.
    Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17(5):677–682.PubMedCrossRefGoogle Scholar
  97. 97.
    Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging 2002;19(2):85–100.PubMedCrossRefGoogle Scholar
  98. 98.
    Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer (Phila) 1998;82(2):395–402.PubMedCrossRefGoogle Scholar
  99. 99.
    Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36(2):177–184.PubMedCrossRefGoogle Scholar
  100. 100.
    Kosty MP, Fleishman SB, Herndon JE II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12(6):1113–1120.PubMedGoogle Scholar
  101. 101.
    Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12(6):1126–1129.PubMedGoogle Scholar
  102. 102.
    Loprinzi CL, Kuross SA, O’Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12(6):1121–1125.PubMedGoogle Scholar
  103. 103.
    Lissoni P, Ardizzoia A, Perego MS, et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993;7(2):73–75.PubMedGoogle Scholar
  104. 104.
    Laviano A, Renvyle T, Yang ZJ. From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Nutrition 1996;12(2):112–122.PubMedCrossRefGoogle Scholar
  105. 105.
    Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993;36(1):57–60.PubMedCrossRefGoogle Scholar
  106. 106.
    Aygene E, Celikkanat S, Kaymakci M, Aksaray F, Ozdem C. Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg 2004;130(3):351–356.CrossRefGoogle Scholar
  107. 107.
    Ozturk B, Egehan I, Atavci S, Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 2004;58(1):213–219.PubMedCrossRefGoogle Scholar
  108. 108.
    Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13(11):2856–2859.PubMedGoogle Scholar
  109. 109.
    Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer (Phila) 1990;65(12):2657–2662.PubMedCrossRefGoogle Scholar
  110. 110.
    Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989;25(12):1823–1829.PubMedCrossRefGoogle Scholar
  111. 111.
    Simons JP, Aaronson NK, Vansteenkiste JF, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996;14(4):1077–1084.PubMedGoogle Scholar
  112. 112.
    Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery (St. Louis) 1995;117(3):260–267.PubMedCrossRefGoogle Scholar
  113. 113.
    Wolf RF, Pearlstone DB, Newman E, et al. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg 1992;216(3):280–288; discussion 288–290.PubMedCrossRefGoogle Scholar
  114. 114.
    Directors AASfPaENBo. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002;26(1 suppl):1SA–138SA.CrossRefGoogle Scholar
  115. 115.
    Hill G. The perioperative patient. In: Kinney J, Jeejeebhoy K, Hill G, Owen O, eds. Nutrition and Metabolism in Patient Care. Philadelphia: Saunders, 1988:643–655.Google Scholar
  116. 116.
    Smale BF, Mullen JL, Buzby GP, Rosato EF. The efficacy of nutritional assessment and support in cancer surgery. Cancer (Phila) 1981;47(10):2375–2381.PubMedCrossRefGoogle Scholar
  117. 117.
    Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg 1980;139(1):160–167.PubMedCrossRefGoogle Scholar
  118. 118.
    Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991;325(8):525–532.Google Scholar
  119. 119.
    Franch-Areas G. The meaning of hypoalbuminaemia in clinical practice. Clin Nutr 2001;20(3):265–269.CrossRefGoogle Scholar
  120. 120.
    Harvey KB, Moldawer LL, Bistrian BR, Blackburn GL. Biological measures for the formulation of a hospital prognostic index. Am J Clin Nutr 1981;34(10):2013–2022.PubMedGoogle Scholar
  121. 121.
    Kirby D, DeLegge M. Nutritional assessment in the high tech and low tech tour. In: Kirby D, Dudrick S, eds. Practical Handbook of Nutrition in Clinical Practice. Boca Raton: CRC Press, 1994:1–18.Google Scholar
  122. 122.
    Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 1996;12(1 suppl):S15–S19.PubMedGoogle Scholar
  123. 123.
    Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;11(1):8–13.PubMedCrossRefGoogle Scholar
  124. 124.
    Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr 2003;57(2):305–309.PubMedCrossRefGoogle Scholar
  125. 125.
    Ottery FD. Instruments of proactive assessment and intervention in the context of outcomes-based research and clinical care. In: Improving Clinical Practice with Nutrition in a Managed Care Environment. Columbus: Ross Products Division, Abbott Laboratories, 1997:29–36.Google Scholar
  126. 126.
    Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer (Phila) 1995;75(8):2077–2082.PubMedCrossRefGoogle Scholar
  127. 127.
    Deehan D, Heys S, Walker L, et al. Serum albumin an indepedent progonostic factor in patients with colorectal cancer. Br J Surg 1995;82:691.CrossRefGoogle Scholar
  128. 128.
    Delmore G. Assessment of nutritional status in cancer patients: widely neglected? Support Care Cancer 1997;5(5):376–380.PubMedCrossRefGoogle Scholar
  129. 129.
    Bozzetti F. Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition 2002;18(11–12):953–959.PubMedCrossRefGoogle Scholar
  130. 130.
    Bozzetti F. Effects of artificial nutrition on the nutritional status of cancer patients. JPEN J Parenter Enteral Nutr 1989;13(4):406–420.PubMedCrossRefGoogle Scholar
  131. 131.
    Lin MT, Saito H, Fukushima R, et al. Preoperative total parenteral nutrition influences postoperative systemic cytokine responses after colorectal surgery. Nutrition 1997;13(1):8–12.PubMedCrossRefGoogle Scholar
  132. 132.
    Daly J, Thorn A. Neoplastic diseases. In: Kinney J, Jeejeebhoy K, Hill G, Owen O, eds. Nutrition and Metabolism in Patient Care. Philadelphia: Saunders, 1988:567–587.Google Scholar
  133. 133.
    Torosian MH. Stimulation of tumor growth by nutrition support. JPEN J Parenter Enteral Nutr 1992;16(6 suppl):72S–75S.PubMedGoogle Scholar
  134. 134.
    Popp MB, Wagner SC, Brito OJ. Host and tumor responses to increasing levels of intravenous nutritional support. Surgery (St. Louis) 1983;94(2):300–308.PubMedGoogle Scholar
  135. 135.
    Torosian MH, Donoway RB. Total parenteral nutrition and tumor metastasis. Surgery (St. Louis) 1991;109(5):597–601.PubMedGoogle Scholar
  136. 136.
    Baron PL, Lawrence W Jr, Chan WM, White FK, Banks WL Jr. Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer. Arch Surg 1986;121(11):1282–1286.PubMedCrossRefGoogle Scholar
  137. 137.
    Frank JL, Lawrence W Jr, Banks WL Jr, McKinnon JG, Chan WM, Collins JM. Modulation of cell cycle kinetics in human cancer with total parenteral nutrition. Cancer (Phila) 1992;69(7):1858–1864.PubMedCrossRefGoogle Scholar
  138. 138.
    Franchi F, Rossi-Fanelli F, Seminara P, Cascino A, Barone C, Scucchi L. Cell kinetics of gastrointestinal tumors after different nutritional regimens. A preliminary report. J Clin Gastroenterol 1991;13(3):313–315.PubMedCrossRefGoogle Scholar
  139. 139.
    Heys SD, Park KG, McNurlan MA, et al. Stimulation of protein synthesis in human tumours by parenteral nutrition: evidence for modulation of tumour growth. Br J Surg 1991;78(4):483–487.PubMedCrossRefGoogle Scholar
  140. 140.
    Bozzetti F, Gavazzi C, Mariani L, Crippa F. Glucose-based total parenteral nutrition does not stimulate glucose uptake by humans tumours. Clin Nutr 2004;23(3):417–421.PubMedCrossRefGoogle Scholar
  141. 141.
    Klein S, Koretz RL. Nutrition support in patients with cancer: what do the data really show? Nutr Clin Pract 1994;9(3):91–100.PubMedCrossRefGoogle Scholar
  142. 142.
    Holter AR, Fischer JE. The effects of perioperative hyperalimentation on complications in patients with carcinoma and weight loss. J Surg Res 1977;23(1):31–34.PubMedCrossRefGoogle Scholar
  143. 143.
    Sako K, Lore JM, Kaufman S, Razack MS, Bakamjian V, Reese P. Parenteral hyperalimentation in surgical patients with head and neck cancer: a randomized study. J Surg Oncol 1981;16(4):391–402.PubMedCrossRefGoogle Scholar
  144. 144.
    Muller JM, Brenner U, Dienst C, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982;1(8263):68–71.PubMedCrossRefGoogle Scholar
  145. 145.
    Yamada N, Koyama H, Hioki K, Yamada T, Yamamoto M. Effect of postoperative total parenteral nutrition (TPN) as an adjunct to gastrectomy for advanced gastric carcinoma. Br J Surg 1983;70(5):267–274.PubMedCrossRefGoogle Scholar
  146. 146.
    Muller JM, Keller HW, Brenner U, Walter M, Holzmuller W. Indications and effects of preoperative parenteral nutrition. World J Surg 1986;10(1):53–63.PubMedCrossRefGoogle Scholar
  147. 147.
    Askanazi J, Hensle TW, Starker PM, et al. Effect of immediate postoperative nutritional support on length of hospitalization. Ann Surg 1986;203(3):236–239.PubMedCrossRefGoogle Scholar
  148. 148.
    Brennan MF, Pisters PW, Posner M, Quesada O, Shike M. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994;220(4):436–441; discussion 441–444.PubMedCrossRefGoogle Scholar
  149. 149.
    Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994;331(23):1547–1552.PubMedCrossRefGoogle Scholar
  150. 150.
    Meijerink WJ, von Meyenfeldt MF, Rouflart MM, Soeters PB. Efficacy of perioperative nutritional support. Lancet 1992;340(8812):187–188.PubMedCrossRefGoogle Scholar
  151. 151.
    Gianotti L, Braga M, Vignali A, et al. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg 1997;132(11):1222–1229; discussion 1229–1230.PubMedGoogle Scholar
  152. 152.
    Sand J, Luostarinen M, Matikainen M. Enteral or parenteral feeding after total gastrectomy: prospective randomised pilot study. Eur J Surg 1997;163(10):761–766.PubMedGoogle Scholar
  153. 153.
    Braga M, Gianotti L, Gentilini O, Parisi V, Salis C, Di Carlo V. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Crit Care Med 2001;29(2):242–248.PubMedCrossRefGoogle Scholar
  154. 154.
    Bozzetti F, Braga M, Gianotti L, Gavazzi C, Mariani L. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 2001;358(9292):1487–1492.PubMedCrossRefGoogle Scholar
  155. 155.
    Aiko S, Yoshizumi Y, Sugiura Y, et al. Beneficial effects of immediate enteral nutrition after esophageal cancer surgery. Surg Today 2001;31(11):971–978.PubMedCrossRefGoogle Scholar
  156. 156.
    Papapietro K, Diaz E, Csendes A, et al. Early enteral nutrition in cancer patients subjected to a total gastrectomy. Rev Med Chil 2002;130(10):1125–1130.PubMedGoogle Scholar
  157. 157.
    Jiang XH, Li N, Li JS. Intestinal permeability in patients after surgical trauma and effect of enteral nutrition versus parenteral nutrition. World J Gastroenterol 2003;9(8):1878–1880.PubMedGoogle Scholar
  158. 158.
    Sagar S, Harland P, Shields R. Early postoperative feeding with elemental diet. Br Med J 1979;1(6159):293–295.PubMedCrossRefGoogle Scholar
  159. 159.
    Smith RC, Hartemink RJ, Hollinshead JW, Gillett DJ. Fine bore jejunostomy feeding following major abdominal surgery: a controlled randomized clinical trial. Br J Surg 1985;72(6):458–461.PubMedCrossRefGoogle Scholar
  160. 160.
    Foschi D, Cavagna G, Callioni F, Morandi E, Rovati V. Hyperalimentation of jaundiced patients on percutaneous transhepatic biliary drainage. Br J Surg 1986;73(9):716–719.PubMedCrossRefGoogle Scholar
  161. 161.
    Heslin MJ, Latkany L, Leung D, et al. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann Surg 1997;226(4):567–577; discussion 577–580.PubMedCrossRefGoogle Scholar
  162. 162.
    Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000;24(1):7–14.PubMedCrossRefGoogle Scholar
  163. 163.
    Hyltander A, Bosaeus I, Svedlund J, et al. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. Clin Gastroenterol Hepatol 2005;3(5):466–474.PubMedCrossRefGoogle Scholar
  164. 164.
    Wu GH, Liu ZH, Wu ZH, Wu ZG. Perioperative artificial nutrition in malnourished gastrointestinal cancer patients. World J Gastroenterol 2006;12( 15):2441–2444.PubMedGoogle Scholar
  165. 165.
    Aiko S, Yoshizumi Y, Matsuyama T, Sugiura Y, Maehara T. Influences of thoracic duct blockage on early enteral nutrition for patients who underwent esophageal cancer surgery. Jpn J Thorac Cardiovasc Surg 2003;51(7):263–271.PubMedCrossRefGoogle Scholar
  166. 166.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348(17):1625–1638.PubMedCrossRefGoogle Scholar
  167. 167.
    Seven H, Calis AB, Turgut S. A randomized controlled trial of early oral feeding in laryngectomized patients. Laryngoscope 2003;113(6):1076–1079.PubMedCrossRefGoogle Scholar
  168. 168.
    August DA. Creation of a specialized nutrition support outcomes research consortium: if not now, when? JPEN J Parenter Enteral Nutr 1996;20(6):394–400.PubMedCrossRefGoogle Scholar
  169. 169.
    Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987;43(6):833–838.PubMedCrossRefGoogle Scholar
  170. 170.
    Charuhas PM, Fosberg KL, Bruemmer B, et al. A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. JPEN J Parenter Enteral Nutr 1997;21(3):157–161.PubMedCrossRefGoogle Scholar
  171. 171.
    Muscaritoli M, Conversano L, Torelli GF, et al. Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation. Transplantation 1998;66(5):610–616.PubMedCrossRefGoogle Scholar
  172. 172.
    Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant 2003;32(7):715–721.PubMedCrossRefGoogle Scholar
  173. 173.
    Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res 1987;47(12):3309–3316.PubMedGoogle Scholar
  174. 174.
    Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992;116(10):821–828.PubMedGoogle Scholar
  175. 175.
    Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN J Parenter Enteral Nutr 1993;17(5):407–413.PubMedCrossRefGoogle Scholar
  176. 176.
    Jordan WM, Valdivieso M, Frankmann C, et al. Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation. Cancer Treat Rep 1981;65(3–4):197–205.PubMedGoogle Scholar
  177. 177.
    Nixon D, Moffitt S, Lawson D, et al. Total parenteral nutrition as an adjunct to chemotherapy for metastatic colorectal cancer. Cancer Treat Rep 1981;65(suppl 5):123–128.Google Scholar
  178. 178.
    Popp MB, Fisher RI, Wesley R, Aamodt R, Brennan MF. A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. Surgery (St. Louis) 1981;90(2):195–203.PubMedGoogle Scholar
  179. 179.
    Samuels ML, Selig DE, Ogden S, Grant C, Brown B. IV hyperalimentation and chemotherapy for stage III testicular cancer: a randomized study. Cancer Treat Rep 1981;65(7–8):615–627.PubMedGoogle Scholar
  180. 180.
    Serrou B, Cupissol D, Plagne R, et al. Follow-up of a randomized trial for oat cell carcinoma evaluating the efficacy of peripheral intravenous nutrition (PIVN) as adjunct treatment. Recent Results Cancer Res 1982;80:246–253.PubMedGoogle Scholar
  181. 181.
    Shamberger RC, Brennan MF, Goodgame JT Jr, et al. A prospective, randomized study of adjuvant parenteral nutrition in the treatment of sarcomas: results of metabolic and survival studies. Surgery (St. Louis) 1984;96(1):1–13.PubMedGoogle Scholar
  182. 182.
    Tandon SP, Gupta SC, Sinha SN, Naithani YP. Nutritional support as an adjunct therapy of advanced cancer patients. Indian J Med Res 1984;80:180–188.PubMedGoogle Scholar
  183. 183.
    Clamon GH, Feld R, Evans WK, et al. Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 1985;69(2):167–177.PubMedGoogle Scholar
  184. 184.
    Valdivieso M, Frankmann C, Murphy WK, et al. Long-term effects of intravenous hyperalimentation administered during intensive chemotherapy for small cell bronchogenic carcinoma. Cancer (Phila) 1987;59(2):362–369.PubMedCrossRefGoogle Scholar
  185. 185.
    Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987;5(1):113–124.PubMedGoogle Scholar
  186. 186.
    De Cicco M, Panarello G, Fantin D, et al. Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status. JPEN J Parenter Enteral Nutr 1993;17(6):513–518.PubMedCrossRefGoogle Scholar
  187. 187.
    Bozzetti F, Cozzaglio L, Gavazzi C, et al. Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival. Tumori 1998;84(6):681–686.PubMedGoogle Scholar
  188. 188.
    Hyltander A, Drott C, Unsgaard B, et al. The effect on body composition and exercise performance of home parenteral nutrition when given as adjunct to chemotherapy of testicular carcinoma. Eur J Clin Invest 1991;21(4):413–420.PubMedCrossRefGoogle Scholar
  189. 189.
    Jin D, Phillips M, Byles JE. Effects of parenteral nutrition support and chemotherapy on the phasic composition of tumor cells in gastrointestinal cancer. JPEN J Parenter Enteral Nutr 1999;23(4):237–241.PubMedCrossRefGoogle Scholar
  190. 190.
    Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer (Phila) 1986;58(6):1378–1386.PubMedCrossRefGoogle Scholar
  191. 191.
    McGeer AJ, Detsky AS, O’Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 1990;6(3):233–240.PubMedGoogle Scholar
  192. 192.
    Parenteral nutrition in patients receiving cancer chemotherapy. American College of Physicians. Ann Intern Med 1989;110(9):734–736.Google Scholar
  193. 193.
    Donaldson SS. Nutritional support as an adjunct to radiation therapy. JPEN J Parenter Enteral Nutr 1984;8(3):302–310.PubMedCrossRefGoogle Scholar
  194. 194.
    Sikora SS, Ribeiro U, Kane JM III, Landreneau RJ, Lembersky B, Posner MC. Role of nutrition support during induction chemo-radiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr 1998;22(1):18–21.PubMedCrossRefGoogle Scholar
  195. 195.
    Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29(6):501–513.PubMedCrossRefGoogle Scholar
  196. 196.
    Heys SD, Gough DB, Khan L, Eremin O. Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Br J Surg 1996;83(5):608–619.PubMedCrossRefGoogle Scholar
  197. 197.
    O’Riordain MG, Fearon KC, Ross JA, et al. Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection. Ann Surg 1994;220(2):212–221.PubMedCrossRefGoogle Scholar
  198. 198.
    Wu GH, Zhang YW, Wu ZH. Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients. World J Gastroenterol 2001;7(3):357–362.PubMedGoogle Scholar
  199. 199.
    Morlion BJ, Stehle P, Wachtler P, et al. Total parenteral nutrition with glutamine dipeptide after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg 1998;227(2):302–308.PubMedCrossRefGoogle Scholar
  200. 200.
    Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr 1999;23(3):117–122.PubMedCrossRefGoogle Scholar
  201. 201.
    Coghlin Dickson TM, Wong RM, Offrin RS, et al. Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J Parenter Enteral Nutr 2000;24(2):61–66.PubMedCrossRefGoogle Scholar
  202. 202.
    Piccirillo N, De Matteis S, Laurenti L, et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192–200.PubMedGoogle Scholar
  203. 203.
    Scheid C, Hermann K, Kremer G, et al. Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 2004;20(3):249–254.PubMedCrossRefGoogle Scholar
  204. 204.
    Daly JM, Lieberman MD, Goldfine J, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery (St. Louis) 1992;112(1):56–67.PubMedGoogle Scholar
  205. 205.
    Senkal M, Kemen M, Homann HH, Eickhoff U, Baier J, Zumtobel V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg 1995;161(2):115–122.PubMedGoogle Scholar
  206. 206.
    Daly JM, Weintraub FN, Shou J, Rosato EF, Lucia M. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995;221(4):327–338.PubMedCrossRefGoogle Scholar
  207. 207.
    Braga M, Gianotti L, Cestari A, et al. Gut function and immune and inflammatory responses in patients perioperatively fed with supplemented enteral formulas. Arch Surg 1996;131(12):1257–1264;discussion 1264–1265.PubMedGoogle Scholar
  208. 208.
    Braga M, Gianotti L, Vignali A, Cestari A, Bisagni P, Di Carlo V. Artificial nutrition after major abdominal surgery: impact of route of administration and composition of the diet. Crit Care Med 1998;26(1):24–30.PubMedCrossRefGoogle Scholar
  209. 209.
    Di Carlo V, Gianotti L, Balzano G, Zerbi A, Braga M. Complications of pancreatic surgery and the role of perioperative nutrition. Dig Surg 1999;16(4):320–326.PubMedCrossRefGoogle Scholar
  210. 210.
    Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology 2002;122(7):1763–1770.PubMedCrossRefGoogle Scholar
  211. 211.
    van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blomberg-van der Flier BM, et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr 2001;73(2):323–332.PubMedGoogle Scholar
  212. 212.
    de Luis DA, Izaola O, Cuellar L, Terroba MC, Aller R. Randomized clinical trial with an enteral arginine-enhanced formula in early postsurgical head and neck cancer patients. Eur J Clin Nutr 2004;58(11):1505–1508.PubMedCrossRefGoogle Scholar
  213. 213.
    Song JX, Qing SH, Huang XC, Qi DL. Effect of parenteral nutrition with L-arginine supplementation on postoperative immune function in patients with colorectal cancer. Di Yi Jun Yi Da Xue Xue Bao 2002;22(6):545–547.PubMedGoogle Scholar
  214. 214.
    Lacour J, Lacour F, Spira A, et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br Med J (Clin Res Ed) 1984;288(6417):589–592.CrossRefGoogle Scholar
  215. 215.
    Lacour J, Laplanche A, Delozier T, et al. Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2% year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.). Breast Cancer Res Treat 1991;19(1):15–21.PubMedCrossRefGoogle Scholar
  216. 216.
    Lacour J, Laplanche A, Malafosse M, et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992;18(6):599–604.PubMedGoogle Scholar
  217. 217.
    Jho DH, Cole SM, Lee EM, Espat NJ. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther 2004;3(2):98–111.PubMedCrossRefGoogle Scholar
  218. 218.
    Hardman WE. Omega-3 fatty acids to augment cancer therapy. J Nutr 2002;132(11 suppl):3508S–3512S.PubMedGoogle Scholar
  219. 219.
    Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22(12):2469–2476.PubMedCrossRefGoogle Scholar
  220. 220.
    Fearon K, von Meyenfeldt MF, Moses A, et al. An energy and protein dense, high n-3 fatty acid oral supplement promotes weight gain in cancer cachexia. Eur J Cancer 2001;37(suppl 6):S27–S28.CrossRefGoogle Scholar
  221. 221.
    Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004;90(5):996–1002.PubMedCrossRefGoogle Scholar
  222. 222.
    Wachtler P, Konig W, Senkal M, Kemen M, Roller M. Influence of a total parenteral nutrition enriched with omega-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery. J Trauma 1997;42(2):191–198.PubMedCrossRefGoogle Scholar
  223. 223.
    Senkal M, Zumtobel V, Bauer KH, et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Arch Surg 1999;134(12):1309–1316.PubMedCrossRefGoogle Scholar
  224. 224.
    Braga M, Gianotti L, Nespoli L, Radaelli G, Di Carlo V. Nutritional approach in malnourished surgical patients: a prospective randomized study. Arch Surg 2002;137(2):174–180.PubMedCrossRefGoogle Scholar
  225. 225.
    Farreras N, Artigas V, Cardona D, Rius X, Trias M, Gonzalez JA. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr 2005;24(1):55–65.PubMedCrossRefGoogle Scholar
  226. 226.
    Chen DW, Wei Fei Z, Zhang YC, Ou JM, Xu J. Role of enteral immunonutrition in patients with gastric carcinoma undergoing major surgery. Asian J Surg 2005;28(2):121–124.PubMedGoogle Scholar
  227. 227.
    Braga M, Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery (St. Louis) 2002;132(5):805–814.PubMedCrossRefGoogle Scholar
  228. 228.
    Koretz RL. Immunonutrition. Surgery (St. Louis) 1993;114(3):631–632.PubMedGoogle Scholar
  229. 229.
    Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001;286(8):944–953.PubMedCrossRefGoogle Scholar
  230. 230.
    Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 2001;358(9283):696–701.PubMedCrossRefGoogle Scholar
  231. 231.
    Bistrian BR. Practical recommendations for immune-enhancing diets. J Nutr 2004;134(10 suppl):2868S–2872S;discussion 2895S.PubMedGoogle Scholar
  232. 232.
    Fainsinger RL, Gramlich LM. How often can we justify parenteral nutrition in terminally ill cancer patients? Palliat Care 1997;13(1):48–51.Google Scholar
  233. 233.
    Howard L. Home parenteral nutrition in patients with a cancer diagnosis. JPEN J Parenter Enteral Nutr 1992;16(6 suppl):93S–99S.PubMedGoogle Scholar
  234. 234.
    Bozzetti F. Home total parenteral nutrition in incurable cancer patients: a therapy, a basic humane care or something in between? Clin Nutr 2003;22(2):109–111.PubMedCrossRefGoogle Scholar
  235. 235.
    August DA, Thorn D, Fisher RL, Welchek CM. Home parenteral nutrition for patients with inoperable malignant bowel obstruction. JPEN J Parenter Enteral Nutr 1991;15(3):323–327.PubMedCrossRefGoogle Scholar
  236. 236.
    King LA, Carson LF, Konstantinides N, et al. Outcome assessment of home parenteral nutrition in patients with gynecologic malignancies: what have we learned in a decade of experience? Gynecol Oncol 1993;51(3):377–382.PubMedCrossRefGoogle Scholar
  237. 237.
    Cozzaglio L, Balzola F, Cosentino F, et al. Outcome of cancer patients receiving home parenteral nutrition. Italian Society of Parenteral and Enteral Nutrition (S.I.N.P.E.). JPEN J Parenter Enteral Nutr 1997;21(6):339–342.PubMedCrossRefGoogle Scholar
  238. 238.
    Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet 1985;2(8462):990–993.PubMedCrossRefGoogle Scholar
  239. 239.
    Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66(6):1191–1308.PubMedGoogle Scholar
  240. 240.
    Willett WC. Diet, nutrition, and avoidable cancer. Environ Health Perspect 1995;103(suppl 8):165–170.PubMedCrossRefGoogle Scholar
  241. 241.
    Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 2001;10(1):3–8.PubMedGoogle Scholar
  242. 242.
    Forman MR, Hursting SD, Umar A, Barrett JC. Nutrition and cancer prevention: a multidisciplinary perspective on human trials. Annu Rev Nutr 2004;24:223–254.PubMedCrossRefGoogle Scholar
  243. 243.
    Schatzkin A. Dietary change as a strategy for preventing cancer. Cancer Metastasis Rev 1997;16(3–4):377–392.PubMedCrossRefGoogle Scholar
  244. 244.
    Hill MJ. Diet and cancer: a review of scientific evidence. Eur J Cancer Prev 1995;4(suppl 2):3–42.PubMedCrossRefGoogle Scholar
  245. 245.
    McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene 2004;23(38):6349–6364.PubMedCrossRefGoogle Scholar
  246. 246.
    Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983;221(4617):1256–1264.PubMedCrossRefGoogle Scholar
  247. 247.
    Chesson A, Collins A. Assessment of the role of diet in cancer prevention. Cancer Lett 1997;114(1–2):237–245.PubMedCrossRefGoogle Scholar
  248. 248.
    Caporaso NE, Tucker MA, Hoover RN, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990;82(15):1264–1272.PubMedCrossRefGoogle Scholar
  249. 249.
    Greenwald P. Chemoprevention of cancer. Sci Am 1996;275(3):96–99.PubMedGoogle Scholar
  250. 250.
    Trichopoulos D, Li FP, Hunter DJ. What causes cancer? Sci Am 1996;275(3):80–87.PubMedGoogle Scholar
  251. 251.
    Weindruch R. Caloric restriction and aging. Sci Am 1996;274(1):46–52.PubMedCrossRefGoogle Scholar
  252. 252.
    Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364(9441):1219–1228.PubMedCrossRefGoogle Scholar
  253. 253.
    Albright CD, Liu R, Mar MH, et al. Diet, apoptosis, and carcinogenesis. Adv Exp Med Biol 1997;422:97–107.PubMedGoogle Scholar
  254. 254.
    Weindruch R, Albanes D, Kritchevsky D. The role of calories and caloric restriction in carcinogenesis. Hematol Oncol Clin N Am 1991;5(1):79–89.Google Scholar
  255. 255.
    Wachsman JT. The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Mutat Res 1996;350(1):25–34.PubMedGoogle Scholar
  256. 256.
    Bostick R. Diet and nutrition in the etiology and primary prevention of colon cancer. In: Bendich A, Deckelbaum R, eds. The Comprehensive Guide for Health Professionals. Totowa: Humana Press, 1997:57–95.Google Scholar
  257. 257.
    Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004;111(5):750–756.PubMedCrossRefGoogle Scholar
  258. 258.
    Kim YI. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 2004;44(1):10–25.PubMedCrossRefGoogle Scholar
  259. 259.
    Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004;23(38):6379–6391.PubMedCrossRefGoogle Scholar
  260. 260.
    Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004;62(5):204–211.PubMedCrossRefGoogle Scholar
  261. 261.
    Aggarwal K, Pahuja S, Chadha R. Botryoid rhabdomyosarcoma of common bile duct. Indian J Pediatr 2004;71(4):363–364.PubMedCrossRefGoogle Scholar
  262. 262.
    Byers T, Nestle M, McTiernan A, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2002;52(2):92–119.PubMedCrossRefGoogle Scholar
  263. 263.
    Spiegel W, Zidek T, Vutuc C, Maier M, Isak K, Micksche M. Complementary therapies in cancer patients: prevalence and patients’ motives. Wien Klin Wochenschr 2003;115(19–20):705–709.PubMedGoogle Scholar
  264. 264.
    Gray RE, Fitch M, Goel V, Franssen E, Labrecque M. Utilization of complementary/alternative services by women with breast cancer. J Health Soc Policy 2003;16(4):75–84.PubMedCrossRefGoogle Scholar
  265. 265.
    Malik IA, Gopalan S. Use of CAM results in delay in seeking medical advice for breast cancer. Eur J Epidemiol 2003;18(8):817–822.PubMedCrossRefGoogle Scholar
  266. 266.
    Henderson JW, Donatelle RJ. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 2004;10(1):52–57.PubMedGoogle Scholar
  267. 267.
    Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 2004;22(4):671–677.PubMedCrossRefGoogle Scholar
  268. 268.
    Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R. A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2003;2(3):212–216.PubMedCrossRefGoogle Scholar
  269. 269.
    Cassileth BR, Chapman CC. Alternative cancer medicine: a ten-year update. Cancer Invest 1996;14(4):396–404.PubMedCrossRefGoogle Scholar
  270. 270.
    Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. N Engl J Med 1998;339(12):839–841.PubMedCrossRefGoogle Scholar
  271. 271.
    DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339(12):785–791.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David A. August
    • 1
    • 2
  • Maureen B. Huhmann
    • 3
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of MedicineNew BrunswickUSA
  2. 2.Dentistry of New Jersey, Robert Wood Johnson Medical SchoolCancer Institute of New JerseyNew BrunswickUSA
  3. 3.Department of Primary CareUniversity of Medicine and Dentistry of New JerseyNew BrunswickUSA

Personalised recommendations